SPARCL Study
From Wikidoc - Reading time: 3 min
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
SPARCL Study On the Web |
|
American Roentgen Ray Society Images of SPARCL Study |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective[edit | edit source]
To study the effects of statins on incidence of recurrent stroke after a recent episode of stroke or transient ischemic attack
Methods[edit | edit source]
Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) was a double blinded study with subjects who had at least one episode of stroke in the last one to six months and LDL levels of 100 to 190 mg/dl with no history of coronary artery disease. These patients were randomly assorted to receive either 80 mg of atorvastatin daily or placebo. The primary end point for the study was first fatal or non-fatal stroke.
Results[edit | edit source]
- During the mean follow up period of 4.9 years, 11.2% of patients from the atorvastatin group and 13.1% of patients from the placebo experienced fatal/non-fatal stroke, with a 5 year absolute risk reduction of 2.2%.
- The 5 year absolute risk reduction in major cardiovascular events was 3.5%.
- The overall mortality rates were similar in both the groups.
Conclusion[edit | edit source]
Atorvastatin (80 mg daily) reduced the incidence of recurrent stroke and cardiovascular events in patients with a recent episode of stroke or transient ischemic attacks. However, the incidence of hemorrhagic stroke increased in the atorvastatin group.[1]
References[edit | edit source]
- ↑ Amarenco P, Bogousslavsky J, Callahan A; et al. (2006). "High-dose atorvastatin after stroke or transient ischemic attack". The New England Journal of Medicine. 355 (6): 549–59. doi:10.1056/NEJMoa061894. PMID 16899775. Unknown parameter
|month=ignored (help)
EncycloReader
is supported by the 
KSF